PHA Case Studies V (Answers)

Similar documents
PHA 5128 CASE STUDY 5 (Digoxin, Cyclosporine, and Methotrexate) Spring 2007

Name: UFID: PHA Exam 2. Spring 2013

TDM Lecture 7 5 th Stage. TDM of Digoxin. Uses: Digoxin is usually used in heart failure associated and atrial fibrillation.

Carbamazepine has a clearance of L/h/kg for monotherapy. For immediate release carbamazepine, the oral bioavailbility is 0.8

PHA 5128 Spring 2009 First Exam (Version B)

TDM of Digoxin. Use of Digoxin Serum Concentrations to Alter Dosages

PHA 5128 Final Exam Spring 2004 Version A. On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA 5128 Spring 2000 Final Exam

Thus, we can group the entire loading dose together as though it was given as a single dose, all administered when the first dose was given.

Case Study 2 Answers Spring 2006

PHA Spring First Exam. 8 Aminoglycosides (5 points)

LD = (Vd x Cp)/F (Vd x Cp)/F MD = (Css x CL x T)/F DR = (Css x (Vm-DR))/Km Css = (F x D)/(CL x T) (Km x DR)/(Vm DR)

. Although there is a little

PHA 5128 Case Study 4 (Answers) Total Cp = Unbound Cp/fu.

Adjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes

PHARMACOKINETICS SMALL GROUP II:

CLINICAL PHARMACOKINETICS INDEPENDENT LEARNING MODULE

pharmacy, we need to see how clinical pharmacokinetics fits into the pharmaceutical care process.

PHA5128 Dose Optimization II Case Study 3 Spring 2013

Basic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy

TDM of Aminoglycoside Antibiotics

A Computer-based Pharmacokinetic Implementation for Digoxin Therapeutic Monitoring in Pediatric Patients

TDM. Measurement techniques used to determine cyclosporine level include:

SHC Vancomycin Dosing Guide

4WS Neurology. Table of Contents

Policy: Created: 2/11/2015; Approved: Adult Pharmacokinetic Dosing and Monitoring- Vancomycin Dosing

PHA 4120 Second Exam Key Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Myrna Y. Munar, Pharm.D., BCPS

PHA Second Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Clinical Pharmacokinetics. Therapeutic Drug Monitoring of Phenytoin

PHA Final Exam Fall 2006

Doses Target Concentration Intervention

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHARMACOKINETICS SMALL GROUP I:

Full title of guideline INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS. control

INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS

Learning Outcomes. Overall Picture. Part 1 Overview of Key Concepts of Clinical Pharmacokine2cs 4/23/14. A- Awaisu- A- Nader- CPPD

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Selected Clinical Calculations Chapter 10. Heparin-Dosing calculations

Career Corner: Pharmaceutical Calculations for Technicians. Ashlee Mattingly, PharmD, BCPS

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Multiple IV Bolus Dose Administration

IV Vancomycin dosing and monitoring Antibiotic Guidelines. Contents. Intro

Principles of Pharmacokinetics

PHA5128 Dose Optimization II Case Study I Spring 2013

New drugs necessity for therapeutic drug monitoring

USES OF PHARMACOKINETICS

1. If the MTC is 100 ng/ml and the MEC is 0.12 ng/ml, which of the following dosing regimen(s) are in the therapeutic window?

PHA 5127 FINAL EXAM FALL On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Use ideal body weight (IBW) unless actual body weight is less. Use the following equation to calculate IBW:

MEDICATION MONITORING: Pharmacist-Managed Intravenous (IV) Vancomycin Protocol

Pharmacokinetic parameters: Halflife

PHENYTOIN DOSING INFORMATION. Adult Dosage

Aminoglycosides. Uses: Treatment of serious gram-negative systemic infections and some grampositive

Section 5.2: Pharmacokinetic properties

Target Concentration Intervention

NIH Public Access Author Manuscript Transplant Proc. Author manuscript; available in PMC 2011 April 6.

Pharmacokinetics Overview

Basic Concepts of TDM

AMINOGLYCOSIDES TDM D O N E B Y

AUGMENTED RENAL CLEARANCE and its clinical implications. Professor Jeffrey Lipman

Lippincott Questions Pharmacology

BIOPHARMACEUTICS and CLINICAL PHARMACY

OMCJH.CHEM.COLL.INF.1001 Therapeutic Drug Monitoring Guidelines

(Max 2 g) = to nearest 250 mg

ANTIBIOTIC DOSE AND DOSE INTERVALS IN RRT and ECMO

2015 Updates in Therapeutics: The Pharmacotherapy Preparatory Review & Recertification Course Pharmacokinetics: A Refresher Curtis L.

D DAVID PUBLISHING. 1. Introduction. Kathryn Koliha 1, Julie Falk 1, Rachana Patel 1 and Karen Kier 2

Gemcitabine + Cisplatin Regimen

Comparative Study of Different Digoxin Treatment Regimens in Egyptian Hospitals. For Partial Fulfillment of Master Degree in Pharmaceutical Sciences

Adult Institutional Pharmacokinetics Protocol

Vancomycin Pharmacokinetics. Myrna Y. Munar, Pharm.D., BCPS Associate Professor of Pharmacy

Bassett Healthcare Clinical Laboratory

Fairview Southdale Hospital Total Points: 50 RN/LPN Medication Assessment Passing: 45

General Principles of Pharmacology and Toxicology

Assessing Renal Function: What you Didn t Know You Didn t Know

Pharmacotherapy Issues in the Pediatric Population

Pharmacokinetic Calculations

Nonparenteral medications

Population Pharmacokinetics and Pharmacodynamics as a Tool in Drug Development. Leon Aarons Manchester Pharmacy School University of Manchester

Valproate Case 3: Formulations Jose de Leon, MD

Pharmacokinetics Applied to the Treatment of Asthma

Clinical Toxicology Toxicity of Digitalis Glycosides 5 th Year (Lab 3)

Medical Mathematics Handout 1.3 Introduction to Dosage Calculations. by Kevin M. Chevalier

What s new with DOACs? Defining place in therapy for edoxaban &

PHAR 7632 Chapter 16

NOAC Prescribing in Patients with Non-Valvular Atrial Fibrillation: Frequently Asked Questions

1 Acute Lymphoblastic Leukaemia

Basic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations

Each tablet contains:

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

Outline. How should we do TDM? Does the evidence support TDM outcomes

BASIC PHARMACOKINETICS

Drug Dosing in Renal Insufficiency. Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila

PHA Final Exam Fall 2001

SLCC Math 1020 Fall 2010 Final Exam Name: Part I: You are not allowed to use calculators, books, or notes. Answer all questions. Do it by yourself.

Chapter-V Drug use in renal and hepatic disorders. BY Prof. C.Ramasamy, Head, Dept of Pharmacy Practice SRM College of Pharmacy, SRM University

RHABDOMYOLYSIS AFTER ADDITION OF DIGITOXIN TO CHRONIC SIMVASTATIN AND AMIODARONE THERAPY

Transcription:

PHA 5128 Case Studies V (Answers) 1. A 100 kg patient is to be treated p.o. with sodium phenytoin capsules. Assuming a phenytoin volume of distribution of 0.7 L/kg, Km of 4 mg/l and Vmax of 7 mg/kg/day, calculate the following: For a 100 kg patient, Vd 0.7 L/kg 100kg 70 L Km 4 mg/l (a) 7mg / day Vmax 100kg 700mg / day k The loading dose to produce an initial concentration of 18 mg/l. How would you administer this dose? For a loading dose to produce a Cp of 18 mg/l, Vd Cp LD (70L)(18mg / L) (0.92)(1) 1369.6 ~ 1370mg Given as IV infusion of 50 mg/min or 3 oral doses of 500, 400, 400 mg every 2hrs. (b) The daily maintenance dose to produce an average steady state concentration of 15 mg/l. The concentration at steady-state is given by D Cpss Cl τ Since phenytoin exhibits nonlinear clearance, Vm Cl Km+ C pss Inserting this expression for Cl into the equation above and solving for dose D gives F:\INTRDEPT\Derendorf\cs5-ans-02.doc 1

Vm C pss τ D ( Km + C pss) S F For Cpss of 15 mg/l, the daily dose is (700mg / day)(15mg / L)(1day) D (4mg / L + 15mg / L)(0.92)(1) 600mg/day 2. A patient (35 years old, 65 kg) is to be started on intravenous phenobarbital sodium. The therapeutic range is 10-30 mg/l. A loading dose is given so as to yield a Cp 0 of 30 mg/l. Calculate this loading dose and the daily maintenance dose to produce an average steady state concentration of 20 mg/l. Based on average PK parameters for a 65 kg patient, Vd (0.7L/kg)(65kg) 45.5L Cl (4 ml/hr/kg)(65 kg) 260 ml/hr 6.24 L/day The loading dose is Vd Cp LD 0 45.5L)(30mg / L) (0.9)(1) 1517mg ~ 1500mg To maintain an average plasma concentration of 20 mg/l, Cl Cpss τ MD ( 6.24L / day)(20mg / L)(1day) (0.9)(1) 138.7 ~ 140 mg/day F:\INTRDEPT\Derendorf\cs5-ans-02.doc 2

3. Estimate a digoxin loading dose that will produce a plasma concentration of 1.5 µg/l for a 70 kg patient R.J., being treated for mild to moderate congestive cardiac failure. How should this loading dose be divided and what would be an appropriate interval between doses? Assume R.J. is a 50- year-old male with a serum creatinine of 1.0 mg/dl. Calculate a maintenance dose that will achieve an average plasma digoxin concentration of 1.5 µg/l. If the patient had had a serum creatinine of 5 mg/dl, would the estimated loading dose have been different? Assuming population average parameters, the Vd for a 70 kg patient is Vd (7.3 L/kg)(70 kg) 511 L (i) Assuming loading dose is administered orally as tablets (S 0.7), Vd Cp LD 0 (511L)(1.5µ g / L) 1095µ g ~ 1000µ g (0.7)(1) (ii) For a 70 kg male patient, 50 y.o. patient with CHF (moderate) and SCr of 1.0 mg/dl, Cl(ml/min) (0.33 ml/min/kg)(weight in kg) + (0.9) Cl creat (in ml/min) In order to use this equation, Cl creat must be determined. Cl creat (140 age)( weight) ( male) 72 Scr (140 50)(70) 87.5ml/ min (72)(1) The digoxin clearance is then Cl (0.33 ml/min/kg)(70) + (0.9)(87.5 ml/min) 1L 60min 24hr 101.9ml/ min 1000ml 1hr 1day 146.7 L/day The daily dose of digoxin is then found to be F:\INTRDEPT\Derendorf\cs5-ans-02.doc 3

Cl C pss τ Dose ( 146.7L / day)(1.5µ g / L)(1day) (0.7)(1) 314.4µg (iii) If Scr is 5 mg/dl rather than 1.0 mg/dl, a different loading dose would be calculated. Although Vd and Cl are independent kinetic parameters, certain disease states may affect them both. An empirical expression for the Vd of digoxin has been derived in terms of Cl creat : Vd(L) (3.8 L/kg)(weight in kg) + (3.1) Cl creat (ml/min) An increased Scr indicates renal dysfunction and a smaller Cl creat. Thus, based on this equation, Vd is decreased and a smaller loading dose is needed, Vd Cp LD 0 F:\INTRDEPT\Derendorf\cs5-ans-02.doc 4

4. GH is a 56 year old liver transplant patient. In the hospital, he received 300 mg QD cyclosporin as an iv infusion which resulted in a trough level of 200 ng/ml. After he is discharged, he will continue with oral cyclosporine treatment. Make a dose recommendation for GH. If 300 mg cyclosporine provides correct plasma levels, dose simply needs to be converted to oral dose (F 0.3) New dose F F current NewFormulation x Current dose 1 (300mg ) 1000mg / day 0.3 Give 500 mg every 12 hours. F:\INTRDEPT\Derendorf\cs5-ans-02.doc 5

5. Camille Carton is a 36 year old female with newly diagnosed atrial fibrillation with accompanying severe obesity. She is 5'7" tall and weights 338 Ibs. Her cardiologist calls the pharmacy and states that he has had trouble in dosing similar patients in the past and would like some assistance in designing a loading and maintenance IV Lanoxin dosage regimen. She has no other complicating drugs or diseases (serum creatinine 0.7 mg%) except that she is being continued on Quinidex Extentabs 300 mg Q8H which she has been reliably taking for 3 years. Respond to the physician's request and in addition, volunteer some helpful TDM guidelines. Upon receiving your recommended digoxin regimen for 5 days, you have the following serum digoxin concentrations: Start date 2/2/92 at 8 a.m., SDC 1.3 ng/ml at 7 a.m. 2/4/92 and 1.7 ng/ml at 7 a.m., 2//7/92. Prepare a follow-up consult and include a warning as to what might be expected if quinidine were discontinued but digoxin remained at the current dosage. Given information: 5'7", 36 y.o. female 338 lbs Scr 0.7 For any calculations, IBW should be used. IBW 45 + 2.3 x (height above 5') 45 + (2.3)(7) 61.1 kg Creatinine clearance may now be calculated: Cl creat (0.852)(140 age) weight (female ) (72) Scr ( 0.85)(140 36)(61.1) (72)(0.7) 107 ml/min Cl and Vd may be estimated using the empirical equations in the text (p. 201) Cl TOT (0.8 ml/min/kg)(ibw) + Cl creat (ml/min) (0.8 ml/min/kg)(61.1 kg) + 107 ml/min 156 ml/min Since quinidine is being co-administered, this value is multiplied by 0.5. Thus, for this patient F:\INTRDEPT\Derendorf\cs5-ans-02.doc 6

Cl TOT (156 ml/min)(0.5) 78 ml/min 1440 min/day 1L/1000 ml 112 L/day Vd 3.8L / kg IBW + 3.1 Cl ( ml creat ( 3.8L / kg)(61.1kg) + (3.1)(107) / min) 564 L (564 L)(0.7) 395 L if on quinidine as well To obtain an initial concentration of 1.5 µg/ml Cp 0 D Vd is solved for D (or LD/loading dose) to give LD Cp 0 Vd (1.5 µg/l)(395 L) 593 ~ 600 µg A maintenance dose to provide the same concentration is MD Cl C pss τ (112 L/day)(1.5 µg/l)(1 day) 168 µg/day ~ 175 µg/day Since two points are given, a better estimate of the clearance for this patient may be obtained using Cl ( Dose / τ) ( Cp Cp average 2 Cp1) Vd t (See page 230-231; see also equation 58 p. 87) F:\INTRDEPT\Derendorf\cs5-ans-02.doc 7

(175µ g / day) Cl 1.5µ g / L 66.5 L/day [(1.7 1.3) µ g / L(564L) /3days] If the patient were to be continued on the current dosing regimen of 175 µg/day, the average would be Cpss D C pss Cl τ 175µ g / day (66.5L / day)(1day) 2.6µ g / L This is above the therapeutic range (although concentrations above 2 µg/l are used for atrial fibrillation according to the book). To provide an average concentration of 1.5 µg/ml, MD Cl C pss τ (66.5 L/day)(1.5 µg/day)(1 day) 99.75 ~ 100 µg/day This dose is small since clearance had been overestimated for this patient. If quinidine were discontinued, clearance would increase (double) and maintenance dose would need to be increased to provide therapeutic concentrations. F:\INTRDEPT\Derendorf\cs5-ans-02.doc 8